In conclusion, our study reports, for the first time, that SNHG1/miR-194/PHLDA1 signalling is involved in the progression of glioma, which leads to a more malignant phenotype and may be a novel potential therapeutic target for glioma. Here, SNHG1 is linked to central nervous system cancer.